Back to top

Analyst Blog

Symmetry Surgical Inc., the wholly-owned subsidiary of orthopedic implants and instruments maker Symmetry Medical (SMA - Analyst Report), recently launched additional neurosurgical line extensions for its Micro Instruments product portfolio. Management believes that the new instruments will benefit neurosurgeons by improving surgical efficiency and clinical results.

The complementary extensions were showcased at the American Association of Neurological Surgeons (“AANS”) meeting in Miami in April 2012.

Symmetry added the Micro Instruments portfolio with its acquisition of the surgical instruments business of Codman & Shurtleff Inc. ("Codman"), a Johnson & Johnson (JNJ - Analyst Report) enterprise. The new products include an instrument tray that can hold the entire set of 33 micro instruments. The tray is specially designed to protect the 2 millimeter bayonetted shafts of the Micro Instrument. The innovative shelf and base of the tray are expected to keep instruments in order during neurosurgical procedures.

Symmetry, in December 2011, completed its acquisition of the surgical instruments portfolio of Codman & Shurtleff. Following the closure of the transaction, the integrated direct general surgical instruments operation, Specialty Surgical Instrumentation ("SSi"), was renamed “Symmetry Surgical”.

Revenues, in the most recent quarter, from the smaller Symmetry Surgical unit soared almost threefold to $26.7 million, buoyed by the Olsen Medical and Codman & Shurtleff acquisitions, which contributed roughly $16.1 million to the division’s sales.

Symmetry is the largest original equipment manufacturer (“OEM”) provider of implants and related surgical instruments and cases to orthopedic devices manufacturers. Its major customers include Johnson & Johnson’s DePuy, Stryker (SYK - Analyst Report) and Zimmer Holdings (ZMH - Analyst Report).

However, Symmetry still faces price and procedure volume pressure on the orthopedic front. Also, the company’s high spending may continue to weigh on its bottom line. Currently, we have a Neutral recommendation on Symmetry. The stock currently retains a short-term Zacks #2 Rank (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%